Puma Biotechnology Files 8-K

TL;DR

Puma Biotech filed an 8-K on 3/19 for an event on 3/18 - details TBD.

AI Summary

Puma Biotechnology, Inc. filed an 8-K on March 19, 2024, reporting an event that occurred on March 18, 2024. The filing indicates 'Other Events' as the item information, but provides no further details within the provided text regarding specific transactions, agreements, or financial figures.

Why It Matters

This filing signifies a material event requiring disclosure by Puma Biotechnology, Inc. to investors, though the specific nature of the event is not detailed in this excerpt.

Risk Assessment

Risk Level: low — The filing itself is a standard disclosure and does not contain information that inherently increases risk; the risk is dependent on the undisclosed event.

Key Players & Entities

• PUMA BIOTECHNOLOGY, INC. (company) — Registrant
• 0001401667 (company) — Central Index Key
• 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
• 10880 Wilshire Blvd, Suite 2150 Los Angeles, CA 90024 (company) — Principal Executive Offices
• INNOVATIVE ACQUISITIONS CORP (company) — Former Company Name

FAQ

Key Financial Figures

• $0.0001 — on which registered Common Stock , $0.0001 par value per share PBYI The Nasdaq

Filing Documents

• pbyi20240319_8k.htm (8-K) — 32KB
• 0001437749-24-008508.txt ( ) — 161KB
• pbyi-20240318.xsd (EX-101.SCH) — 3KB
• pbyi-20240318_def.xml (EX-101.DEF) — 11KB
• pbyi-20240318_lab.xml (EX-101.LAB) — 15KB
• pbyi-20240318_pre.xml (EX-101.PRE) — 11KB
• pbyi20240319_8k_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events On September 22, 2021, Puma Biotechnology, Inc. (the "Company") and Wyeth LLC ("Wyeth"), as co-plaintiffs, filed suit against AstraZeneca Pharmaceuticals, LP, AstraZeneca AB (together "AstraZeneca"), and AstraZeneca PLC for infringement of United States Patent Nos. 10,603,314 ("the '314 patent") and 10,596,162 ("the '162 patent") ( Puma Biotechnology, Inc. et al. v. AstraZeneca Pharmaceuticals LP et al. , 1:21CV01338 (D. Del. Sep. 22, 2021)). The Company's complaint alleges that AstraZeneca's commercial manufacture, use, offer for sale, sale, distribution, and/or importation of Tagrisso (osimertinib) products for the treatment of gefitinib and/or erlotinib-resistant non-small cell lung cancer infringes the '314 and '162 patents. The Company is an exclusive licensee of the '314 and '162 patents under the Pfizer Agreement. Plaintiffs seek a judgment that AstraZeneca's product infringes the asserted patents and an award of monetary damages in an amount to be proven at trial. AstraZeneca filed an answer and counterclaims on November 5, 2021, including claims challenging the asserted patents as not infringed and/or invalid, and accusing plaintiffs of unclean hands and patent misuse. On March 18, 2024, the court denied AstraZeneca's motion for invalidity, denied AstraZeneca's motion for summary judgment of non-infringement, except as to pre-issuance damages, and denied Plaintiffs' motion for summary judgment on AstraZeneca's advice of counsel defense. The court denied the plaintiffs' and defendants' motions to exclude certain expert testimony. AstraZeneca also moved to dismiss both the Company and Wyeth as plaintiffs for lack of constitutional standing. The court denied the motion to dismiss with respect to Wyeth and granted the motion with respect to the Company. The Company was dismissed as a plaintiff in the matter, but remains a counterclaim-defendant in the action. Under the Company's worldwide exclusive license agreement with Pfizer, Inc.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Puma Biotechnology, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 19, 2024 PUMA BIOTECHNOLOGY, INC. a Delaware Corporation By: /s/ Alan Auerbach Name: Alan H. Auerbach Title: Chief Executive Officer, President and Chairman of the Board

View Full Filing

View this 8-K filing on SEC EDGAR